Literature DB >> 20495735

Matrix metalloproteinases involvement in pathologic conditions.

Cornelia Amălinei1, Irina Draga Căruntu, Simona Eliza Giuşcă, Raluca Anca Bălan.   

Abstract

Matrix metalloproteinases (MMPs) have a great variability that provides a complex intervention in pathophysiological conditions. MMPs roles in pathology may be grouped into the following main types: (1) tissue destruction, as in cancer invasion and metastasis, rheumatoid arthritis, osteoarthritis, different types of ulcers, periodontal disease, brain injury and neuroinflammatory diseases; (2) fibrosis, as in liver cirrhosis, fibrotic lung disease, otosclerosis, atherosclerosis, and multiple sclerosis; (3) weakening of matrix, as in dilated cardiomyopathy, epidermolysis bullosa, aortic aneurysm and restenotic lesions. Recent data also adds new MMPs functions in angiogenesis and apoptosis. Interesting opposite intervention in escaping mechanisms vs. antitumor defensive mechanisms had been also reported. As MMP-7 is expressed by tumor cells of epithelial and mesenchymal origin, it may be used as a biological marker of an aggressive phenotype and as a target of therapeutic intervention. MMPs play a pivotal role in the pathogenesis of arthritis, atherosclerosis, pulmonary emphysema, and endometriosis. Although MMP involvement in pathology is more than simple excessive matrix degradation, or an imbalance between them and their specific tissular inhibitors (TIMPs), MMP inhibition may be of therapeutic benefit, so synthetic MMPs inhibitors had been developed and are currently under clinical testing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20495735

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  78 in total

1.  Neurovascular and neuroimmune aspects in the pathophysiology of rosacea.

Authors:  Verena D Schwab; Mathias Sulk; Stephan Seeliger; Pawel Nowak; Jerome Aubert; Christian Mess; Michel Rivier; Isabelle Carlavan; Patricia Rossio; Dieter Metze; Jörg Buddenkotte; Ferda Cevikbas; Johannes J Voegel; Martin Steinhoff
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

2.  Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.

Authors:  Li-Che Lu; Chung-Wei Yang; Wen-Yeh Hsieh; Wan-Hsuan Chuang; Yi-Chang Lin; Chih-Sheng Lin
Journal:  Clin Exp Nephrol       Date:  2015-12-28       Impact factor: 2.801

3.  Human leucine zipper protein sLZIP induces migration and invasion of cervical cancer cells via expression of matrix metalloproteinase-9.

Authors:  Hyereen Kang; Sung-Wuk Jang; Jesang Ko
Journal:  J Biol Chem       Date:  2011-10-18       Impact factor: 5.157

Review 4.  G Protein Coupled Receptor-mediated Transactivation of Extracellular Proteases.

Authors:  Allison E Schafer; Burns C Blaxall
Journal:  J Cardiovasc Pharmacol       Date:  2017-07       Impact factor: 3.105

5.  Wound healing genes and susceptibility to cutaneous leishmaniasis in Brazil: role of COL1A1.

Authors:  Lucas Almeida; Joyce Oliveira; Luiz Henrique Guimarães; Edgar M Carvalho; Jenefer M Blackwell; Léa Castellucci
Journal:  Infect Genet Evol       Date:  2015-01-03       Impact factor: 3.342

6.  Immunohistochemical expression of matrix metalloproteinase-1, matrix metalloproteinase-2 and matrix metalloproteinase-9, myofibroblasts and Ki-67 in actinic cheilitis and lip squamous cell carcinoma.

Authors:  Bianca C Bianco; Fernanda M Scotti; Daniella S C Vieira; Michelle T Biz; Renata G Castro; Filipe Modolo
Journal:  Int J Exp Pathol       Date:  2015-10-30       Impact factor: 1.925

7.  MMP26: A potential biomarker for prostate cancer.

Authors:  Teng Cheng; Fei Li; Rui Wei; Meng-Qin Lv; Yin Zhou; Yun Dai; Yuan Yuan; Gui-Ying Jiang; Ding Ma; Qing-Lei Gao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-12-21

Review 8.  Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.

Authors:  Ralf G Rempe; Anika M S Hartz; Björn Bauer
Journal:  J Cereb Blood Flow Metab       Date:  2016-06-20       Impact factor: 6.200

9.  MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways.

Authors:  Minyoung Youn; Haigen Huang; Cheng Chen; Sharon Kam; Mark C Wilkes; Hee-Don Chae; Kunju J Sridhar; Peter L Greenberg; Bertil Glader; Anupama Narla; Shuo Lin; Kathleen M Sakamoto
Journal:  Blood Adv       Date:  2019-09-24

10.  Expression of VEGF and MMP-9 and MRI imaging changes in cerebral glioma.

Authors:  Yang Liu; Yang Zhou; Xiu-Shi Zhang; Bao-Zhong Shen
Journal:  Oncol Lett       Date:  2011-08-17       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.